Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc., as indicated in the metadata) on May 11, 2023. The filing serves to announce the results of operations for the first quarter ended March 31, 2023. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol VIRI.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this document.
- Revenue, Profit, Cash Flow, Margins: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The specific operational results and comparisons are contained in the referenced press release (Exhibit 99.1), which is not included in the input text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document explicitly states that the information in the press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is Virios Therapeutics, Inc., not Dogwood Therapeutics, Inc.
- Locate and review Exhibit 99.1 (the Press Release dated May 11, 2023) to obtain actual Q1 2023 financial figures.
- Confirm the trading symbol VIRI on the Nasdaq Capital Market.
- Note that the financial data in the press release is furnished and not subject to the liabilities of Section 18 of the Exchange Act.